Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Metastatic cancer (cancer that has spread), drawn from the whole corpus: 598 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Metastasis itself has no approved drug: treatments target the growing cells, not the spreading.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA), Metastasis, Oligometastatic disease. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Which patients with limited spread truly benefit from treating every site is still being tested in phase 3 trials.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA), Metastasis, Oligometastatic disease. Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 16 changes by month →When this page itself was last checked or edited.
Repotrectinib produced responses in 79 percent of ROS1 inhibitor-naive patients (median progression-free survival 35.
Pancreatic cancer cohort: objective response in 7 of 21 patients (33.
Biliary cohort ORR 5.
Cognitive failure hazard ratio 0.
Five-year survival more than doubles with stereotactic radiotherapy to all metastases in the randomised phase 2 trial.